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analysis of 24-month follow-up data from a randomized controlled trial was performed at Tübingen University
Women’s Hospital between November 1, 2012 and May 30, 2015. Premenopausal patients, at least 18 years of
age, who were menstruating, were randomly assigned to be treated for symptomatic uterine ﬁbroids with either
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responses to validated questionnaires and long-term safety. Results: The study enrolled 51 patients; 21 and 22
patients in the RFVTA and laparoscopic myomectomy groups, respectively, completed 24 months of follow-up.
Improvements in the severity of symptoms from baseline were reported by participants in both the RFVTA
(P b 0.001) and laparoscopicmyomectomygroups (P=0.001). A signiﬁcant improvement in health-related quality
of life was observed in the laparoscopic myomectomy group (P = 0.040); a non-signiﬁcant improvement was
recorded in the RFVTA group (P = 0.083). A trocar-site hematoma occurred in one patient in the laparoscopic
myomectomy group. Further surgical interventions were recorded in three patients in the RFVTA group but
these were unrelated to ﬁbroid symptoms. Conclusions: These 24-month data suggest equivalence in safety and
patient-reported efﬁcacy of RFVTA and laparoscopic myomectomy.
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Radiofrequency volumetric thermal ablation1. Introduction
Targeted radiofrequency ablation (RFA) of tissue for palliative and
therapeutic applications has been well documented in the literature
for the treatment of cardiac arrhythmias [1], neurological and spinal
disorders [2,3], and cancers of the liver [4], kidney [5], prostate [6],
breast [7], lung [8], and skin [9]. However, to date only one RFA system,
employing radiofrequency volumetric thermal ablation (RFVTA) has re-
ceived FDA approval for the treatment of symptomatic uterine ﬁbroids
in the United States (Acessa; Halt Medical, Inc, Brentwood, CA, USA).
RFVTA has also been approved for use in Europe.
Uterine ﬁbroids are the most ubiquitous benign uterine masses in
reproductive-aged women, occurring in up to 80% of this group; ofs and Gynecology, University
72067 Tübingen, Germany.
(M. Hahn).
logy and Obstetrics. Published bythese individuals, 25%–30% experience related bleeding, pain, and
bulk symptoms [10,11]. Symptomatic ﬁbroids are a signiﬁcant
healthcare and economic burden worldwide, signiﬁcantly affecting
patients’ quality of life. Treatment success is usually evaluated in
terms of improvements in quality of life. Traditionally, hysterectomy
was the approach employed in the treatment of ﬁbroids; however,
patients have increasingly sought minimally invasive, uterine-
sparing therapies that also preserve reproduction function. Conse-
quently, excisional laparoscopic myomectomy is considered the
gold standard bymost clinicians [12]. Similarly, RFVTA is a minimally
invasive and uterine-sparing procedure. It is guided intraoperatively
using laparoscopic ultrasound, which has been demonstrated to
detect more uterine ﬁbroids (regardless of their location and size)
than either transvaginal ultrasound or contrast-enhanced magnetic
resonance imaging [13]. RFVTA delivers well-controlled thermal
treatment zones without affecting surrounding tissues or organs
and it can be applied to large ﬁbroids, multiple ﬁbroids, and deep
intramural ﬁbroids [14,15].Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
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gauging the success of any treatment for uterine ﬁbroids. The Uterine Fi-
broid Symptom and Quality of Life (UFS–QOL) questionnaire provides
valid, and highly responsive and reliable measures for assessing the
symptoms and health-related quality of life in patientswith symptomatic
uterine ﬁbroids; additionally, it can be used to compare outcomes of
ﬁbroid therapies [16,17]. Similarly, the EuroQoL (EQ-5D) health-state
survey is a validated, multi-attribute health-state classiﬁcation system
that indicates the burden of illness in terms of mobility, self-care, ability
to complete normal activities, pain/discomfort, and anxiety or depression
[18]. The menstrual impact questionnaire (MIQ) is especially useful for
gauging the burden of menstrual bleeding a patient is experiencing at
the time of questioning [19].
The aim of the present interim analysis was to analyze the 24-month
efﬁcacy and safety outcomes from an ongoing randomized controlled
trial of laparoscopic ultrasound-guided RFVTA and laparoscopic
ultrasound-guided myomectomy (ClinicalTrials.gov: NCT01750008)
[15,20] for the treatment of symptomatic uterine ﬁbroids.2. Materials and methods
An interim analysis was performed on data from an ongoing ran-
domized, prospective, single-center, longitudinal trial of laparoscopic
myomectomyand RFVTA that beganNovember 1, 2012. Premenopausal
patients whoweremenstruating, aged at least 18 years, with symptom-
atic ﬁbroids, who desired uterine conservation, and were indicated for
surgical intervention for their ﬁbroid symptoms were referred to
Tübingen University Hospital, Germany, for study enrollment between
November 1, 2012 and June 30, 2013. Eligible patients had a uterine
size of no more than 16 gestational weeks, no individual ﬁbroid with a
largest dimension of greater than 10 cm on transvaginal ultrasound,
and a normal Papanicolaou test. Exclusion criteria included being at
risk for, or known to have, signiﬁcant intra-abdominal adhesions that
would require extensive dissection to mobilize and view all surfaces of
the uterus; pregnancy or lactation; having received any depot
gonadotropin-releasing hormone agonist within the 3 months prior to
the procedure; the presence of an implanted intrauterine or fallopian
tube device at any time up to 10 days before treatment; known or
suspected endometriosis or adenomyosis; pelvic inﬂammatory
disease; gynecologic malignancy or pre-malignancy in the 5 years
before enrollment; history of pelvic radiation; the presence of a
non-uterine pelvic mass larger than 3 cm at its greatest diameter or
the presence of a cervical ﬁbroid; one or more intracavitary (Type 0
or Type 0/1) ﬁbroids that would be better treated by hysteroscopic
means; and not willing to be randomized for treatment. The study
protocol required that patients provide written informed consent
after agreeing that they understood the study purpose, the associat-
ed testing, procedures, and follow-up assessments, as well as the
potential risks and beneﬁts of participation. The Clinical Ethics
Committee of Tübingen University Hospital in Tübingen, Germany
approved the study, and all enrollees were treated at Tübingen
University Hospital. Data were collected and monitored (CenTrial
GmbH, Tübingen, Germany) in Tübingen and were analyzed by an
independent biostatistics ﬁrm in the United States (Innovative
Analytics Inc, Kalamazoo, Michigan USA).
Patients were randomly allocated in a 1:1 ratio to receive either
laparoscopic myomectomy or RFVTA. Randomization occurred as
an intraoperative step after the surgeon mapped the patient’s uterus
for the location, number, and types of ﬁbroids using laparoscopic
ultrasound. The use of laparoscopic ultrasound provided additional
imaging information to the surgeon regarding the patient’s ﬁbroids,
regardless of their treatment assignment. After mapping, the operat-
ing room staff drew an envelope containing the patient’s computer-
generated treatment assignment. Assignments were generated by an
independent biostatistician in blocks of six or four. The surgeon andpatient were masked to treatment assignment prior to the beginning
of surgery.
Patients assigned to undergo myomectomy were placed in the
lithotomy position and underwent standard laparoscopic myomectomy
[15]. If deep intramural ﬁbroids or transmural ﬁbroids not encroaching
on the serosal borders were encountered, two-layer suturing was used.
Although the excision of all ﬁbroids was allowed per protocol, intramu-
ral ﬁbroids 1.0–1.5 cm in diameter were not excised owing to the
clinical standard of care at the study institution.
The RFVTA treatment procedure and the methods for pretreatment
tissue sampling for histopathology have been described in detail
previously [15,20–23]. RFVTA treatment involved the use of a
monopolar radiofrequency generator, a percutaneously placed
handpiece incorporating an electrode at its distal tip with a deployable
array, two large dispersive electrode pads, extension cables, and an
activating foot pedal. Current was delivered to the small electrode tip
and array; this facilitated the localization of ablative treatment to the
ﬁbroid tissue. The current was removed via large dispersive electrode
pads that were placed on each patient’s thighs above the patella. The
electrical current resulted in the oscillation of intracellular ions,
generating resistive or frictional heating. The heat spread by conduc-
tion, decreasing rapidly with increasing distance from the electrode
(1/d4) (Fig. 1A, B, and C). The current continued through the body to
the dispersive electrode pads, where it returned to the source. The
ablated tissue underwent coagulative necrosis and was naturally
reabsorbed by the surrounding myometrium.
The target ablation temperature was 100 °C and the required time at
the target temperature was a function of the length of array deploy-
ment. An algorithm was used to deﬁne the deployment and time at
100 °C. Following the completion of the recommended ablation
time the surgeon depressed the foot pedal, ending the ablation. The
array was then withdrawn into the handpiece shaft, the probe was
switched from ablation to coagulationmode, and the track was coag-
ulated during handpiece withdrawal. Hemostasis was conﬁrmed
through laparoscopic viewing. Following the ablation of all ﬁbroids,
the pelvis was irrigated and inspected, the port sites were closed
using intracutaneous sutures, and patients were discharged from
the clinic on the same day.
The primary outcome of the ongoing 5-year randomized controlled
trial is the length of hospital stay. The secondary outcomes are patients’
responses to questionnaires. The analyses of patient hospitalization and
perioperative outcomes have been described previously [15].
The present interim analysis of the study reports 24-month
postoperative qualitative outcomes in terms of participants’ responses
to questionnaires (UFS–QOL, EQ-5D, overall treatment effect survey,
and the MIQ [16–19]), re-interventions for ﬁbroid symptoms, and
pregnancy outcomes. According to the study method, the participants
will be followed for a total of 5 years.
The calculation of the sample size has been described in detail
previously [15] and was based on hospitalization times for patients in
each group. Brieﬂy, the null hypothesis was that the duration of
hospitalization for patients who underwent the RFVTA procedure
would be more than 10% longer than that experienced by patients
who underwent laparoscopic myomectomy. The alternative hypothesis
was that this would not be the case, resulting in a one-sided non-
inferiority test of RFVTA in comparisonwith laparoscopicmyomectomy,
with an alpha level of 0.025. Based on procedures in the USA
(unpublished data), the null hypothesis would be rejected if the mean
length of hospital stay for patients undergoing RFVTA was 7 ± 4 hours.
The mean length of hospital stay for women undergoing laparoscopic
myomectomy has been demonstrated to be approximately 15 ±
16 hours [24]. The pooled standard deviation of the difference in length
of hospital stay between these two procedures is 11.7 hours, which is
the square root of the mean of the estimated variances of the two
procedures. The power yielded under these assumptions is 0.80, resulting
in a necessary sample size of 50 participants (25 in each group).
Fig. 1. Representative illustrations of the radiofrequency volumetric thermal ablation sequence. (a) At the beginning of treatment, the tissue temperature along the electrodes begins to
increase rapidly. (b) Approximately halfway through treatment, the tissue closest to the electrodes reaches the target temperature while a thermal front 55 °C in temperature expands.
(c) At the end of the treatment, the ablation volume reaches its maximum size and the outer boundary has reached thermal equilibrium with the surrounding tissue. Abbreviation:
RFVTA, radiofrequency volumetric thermal ablation.
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secondary-outcome analyseswere summarized usingdescriptive statis-
tics, and categorical variables were expressed as frequencies and per-
centages. The precision of the questionnaire response outcomes was
summarized using 95% conﬁdence intervals (95% CIs). The two groups
were compared using a Student t test unless noted otherwise. P b 0.05
was considered statistically signiﬁcant. All analyses were performed
using SAS version 9.3 (SAS Institute, Cary, NC, USA).
3. Results
A total of 51 patients were enrolled in the present study; 26 were
randomized to undergo RFVTA treatment and 25 were allocated to the
laparoscopic myomectomy group (Fig. 2). At 24 months, 21 patients in
the RFVTA group and 22 patients in the laparoscopic myomectomy
were available for analysis. The baseline demographics and intraopera-
tive ﬁbroid characteristics are detailed in table 1. Participants in both
groups were similar in terms of their height, weight, and ethnicity;
however, participants allocated to the RFVTA group were found to be
signiﬁcantly older (P = 0.006). Intraoperative mapping revealed the
location and size of ﬁbroids in patients in each group, with a greater
number of ﬁbroids found in patients in the RFVTA group compared
with in patients in the myomectomy group (72 vs 61). Of the ﬁbroidsmapped, 71 (99%) were accessible and were treated in the RFVTA
group comparedwith 49 (80%)ﬁbroids thatwere accessible for excision
using laparoscopic myomectomy [15].
Symptoms experienced by participants at baseline and at 24months
are detailed in table 2. Participants were asked at both timepoints
whether they had experienced each symptom; all responses were
binary (yes or no), with the severity of each symptom not recorded.
There were no signiﬁcant differences observed between the treatment
groups in terms of the symptoms experienced at baseline and at
24-month follow-up.
Changes in mean transformed UFS–QOL scores from baseline to
24-month follow-up are presented in Fig. 3a and b, respectively.
Signiﬁcant improvements in symptom severity frombaseline (indicated
by decreasing values) were recorded in the RFVTA (−54% [95%
CI −72.3 to −34.8]; P b 0.001) and laparoscopic myomectomy
(−45% [95% CI−68.9 to−20.9]; P= 0.001) groups. An improvement
frombaseline (indicated by increasing values) in health-related quality-
of-life scores were reported for the laparoscopic myomectomy group
(21% [95% CI 1.1 to 40.5]; P = 0.040); a non-signiﬁcant improvement
was observed in the RFVTA group (11% [95% CI −1.6 to 23.0]; P =
0.083). As can be observed from Fig. 3a and b, at baseline, participants
in the laparoscopic myomectomy group had higher symptom severity
and lower quality of life than patients in the RFVTA group.
Assessed for eligibility (n=110)
Excluded (n=54)




Patient had a large fibroid (>10 cm) 
and an intrauterine device implanted 
(n=1)
Patient had many fibroids that would 
have necessitated a hysterectomy if 
assigned to the laparoscopic 
myomectomy group (n=2)
Patient had no fibroids (n=1)
Patient had only 1 large 
pedunculated fibroid (>10 cm) (n=1)
Allocated to RFVTA (n=26) Allocated to laparoscopic 
myomectomy (n=25)
Analyzed at 24 months (n=21) Analyzed at 24 months (n=22)
Excluded (n=5)
Did not receive allocated 
intervention owing to 









Fig. 2. Flow of participants through the study.
Table 1





group (n = 25)
Age, y 40.0 ± 7.8 34.4 ± 6.1
Height, cm 166.0 ± 5.8 165.2 ± 5.8
Weight, kg 62.4 ± 8.9 64.9 ± 13.5
Ethnicity
White 25 (100) 25 (100)
Intraoperative ﬁbroid characteristicsb
Total ﬁbroids 72 61
No. of ﬁbroids per patient 2.9 ± 2.6 (2; 1–9) 2.4 ± 1.6 (2; 1–6)
Fibroid type
Submucosal 0 2 (3)
Transmural 0 3 (5)
Intramural 33 (46) 26 (43)
Intramural ﬁbroid abutting the
endometrium
2 (3) 0
Subserosal 37 (51) 34 (56)
Pedunculated subserosal 0 2 (3)
Abbreviation: RFVTA, radiofrequency volumetric thermal ablation.
a Values are given asmean±SD, number (percentage), number, ormean±SD (median;
range), unless indicated otherwise.
b Intraoperative ﬁbroid characteristics were evaluated by laparoscopic ultrasound
mapping of the uterus prior to ablation/excision.
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improvements in mean scores between baseline and 6-month follow-
up for the RFVTA group (81.7±11.2 vs 88.9±13.7) and the laparoscopic
myomectomy group (72.3 ± 18.2 vs 85.3 ± 14.1). However, lower
12-month EQ-5D scores were reported by both the RFVTA (85.5 ±
14.1) and laparoscopic myomectomy (82.9 ± 16.1) groups. At
24 months, the EQ-5D score had improved slightly in the RFVTA group
(86.4±9.7) and had decreased further in the laparoscopicmyomectomy
group (79.3 ± 25.2).
In the overall treatment-effect survey, participants were asked to
compare their symptoms at 24 months with their symptoms at
12 months. In total, 21 patients responded in each group; 8 (38%)
patients in the RFVTA group reported that their ﬁbroid symptoms
were better, 12 (57%) reported that they were about the same, and 1
(5%) reported that their symptoms were worse. In the laparoscopic
myomectomy group, 5 (24%) participants reported that their symptoms
had improved and 16 (76%) reported that their symptoms had
remained the same. In terms of treatment satisfaction, 19 (90%) and
21 (100%) patients in the RFVTA and laparoscopicmyomectomygroups,
respectively, were satisﬁed with the treatment they received. Among
the RFVTA and laparoscopic myomectomy groups, 19 (90%) and 20
(95%) patients, respectively, reported that they would recommend the
treatment they received to a friend who had uterine ﬁbroids. Finally,
in response to the overall treatment effect survey, 14 (67%) and 4
Table 2
Symptoms experienced by patients at enrollment and 24 months.a










Heavy menstrual bleeding 21 (84) 18 (72) 0.31b 6 (29) 3 (14) 0.28c
Pelvic discomfort/pain 10 (40) 11 (44) 0.77b 2 (10) 5 (23) 0.41c
Increased abdominal girth 7 (28) 5 (20) 0.51b 3 (14) 1 (5) 0.35c
Frequent urination 13 (52) 9 (36) 0.25b 4 (19) 2 (9) 0.41c
Urinary retention 4 (16) 8 (32) 0.19b 0 0
Dysmenorrhea 7 (28) 8 (32) 0.78b 8 (38) 7 (32) 0.67b
Dyspareunia 3 (12) 6 (24) 0.46c 2 (10) 3 (14) N0.99c
Backache 7 (28) 6 (24) 0.75b 3 (14) 8 (36) 0.10b
Sleep disturbances 0 1 (4) N0.99c 2 (10) 2 (9) N0.99c
Uterine pain 3 (12) 1 (4) 0.61c 5 (24) 3 (14) 0.46c
Localized pain 5 (20) 5 (20) N0.99b 2 (10) 1 (5) 0.61c
Other 0 1 (4) N0.99c 0 0
Abbreviation: RFVTA, radiofrequency volumetric thermal ablation.
a Values are given as number (percentage) unless indicated otherwise.
b χ2 test.
c Fisher exact test.
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moderately effective and very effective, respectively, in eliminating
their symptoms. In the laparoscopic myomectomy group, 5 (24%) and
13 (62%) patients reported treatment to be moderately effective and
very effective, respectively.
The MIQ survey was used to assess participants’ perceptions of
menstrual bleeding from each patient’s previous period to the point
the survey was conducted. Data from the MIQ survey were available


























































































Fig. 3.Uterine ﬁbroid symptom and quality-of-life scores between study initiation and 24-
month follow-up. (a) Symptom severity scores. (b) Health-related quality-of-life scores.
Abbreviation: RFVTA, radiofrequency volumetric thermal ablation.as, “better” than during their previous period and 11 (61%) described
the blood loss as, “about the same”. Among the 20 patients in the
laparoscopic myomectomy group who responded to the MIQ survey, 4
(20%) described their blood loss as, “better”, 13 (65%) thought it was,
“about the same”, and 3 (15%) described it as, “worse”.
In the RFVTA group, one serious complication occurred in a
participant who presented with hypermenorrhea shortly after the
RFVTA procedure. A physician not afﬁliated with the present study
performed a dilation and curettage procedure; this resulted in uterine
perforation and subsequent hysterectomy. Another patient underwent
a preemptive hysterectomy after a biopsy demonstrated the presence
of a smooth muscle tumor of uncertain malignant potential. A
histopathology report describing the uterus and ﬁbroids revealed no
atypia and conﬁrmed an absence of malignancy. A third participant in
the RFVTA group, who was asymptomatic at 6 months and who stated
a desire to become pregnant in the future, sought a myomectomy
procedure after a 4-cm ﬁbroid was observed during an ultrasound
examination. In the laparoscopic myomectomy group, one patient
experienced a hematoma at the trocar site. No participants in the
laparoscopic myomectomy group sought surgical re-intervention
owing to ﬁbroid symptoms. No other adverse events occurred among
the study participants.
In the RFVTA group, three patients conceived; two pregnancies con-
cluded with vaginal deliveries of healthy neonates and one pregnancy
resulted in a cesarean delivery of a healthy neonate. In the laparoscopic
myomectomy group, six conceptionswere experienced by a total of ﬁve
patients. Of these, one induced abortion, two vaginal deliveries, and two
cesarean deliveries were recorded, with one pregnancy ongoing at the
time of writing.
4. Discussion
The present study demonstrated beneﬁts in terms of safety,
symptom reduction, and improvements in quality of life in patients at
24 months after treatment for symptomatic uterine ﬁbroids with
RFVTA and laparoscopic myomectomy. The evaluations included in
the present study were based on patient responses to validated
questionnaires. The analyzed data from patient responses to these
questionnaires suggests long-termutility of both RFVTA and laparoscopic
myomectomy as treatment options for patients with symptomatic
uterine ﬁbroids who desire uterine conservation.
Although, three patients in the RFVTA group sought further surgical
interventions, none of these was related to ﬁbroid symptoms. Rather,
one decision to undergo hysterectomywas based on the histopatholog-
ical diagnosis of a smooth muscle tumor of uncertain malignant
211B. Krämer et al. / International Journal of Gynecology and Obstetrics 133 (2016) 206–211potential, which could not be conﬁrmed in the ﬁnal specimen of the
removed uterus. Another patient required a hysterectomy following
the perforation of the uterus during a dilation and curettage procedure.
Finally, a patient who wished to become pregnant sought treatment to
excise a newly discovered or re-growing 4-cm ﬁbroid, which was
diagnosed using ultrasound and was not clinically symptomatic.
Guido et al. reported 2-year clinical outcomes of a prospective
multicenter trial of RFVTA conducted in the USA, Guatemala, and
Mexico [25]. Although this study provided strong evidence for the use
of RFVTA in the treatment of symptomatic ﬁbroids, it lacked the
strength of a comparative randomized trial. That the participant popula-
tion in the present studywas racially homogenous can be considered to
be both a strength and a limitation. A racially homogenous group pro-
vides a control for outcomes based on ethnicity but does not provide
the heterogeneity observed in real-world populations of individuals
with symptomatic ﬁbroids. Another limitation is the size of the study.
Although it was powered for the primary outcome of hospitalization
time, it was not sufﬁciently powered to perform a statistical analysis
of the secondary outcomes (the various questionnaire responses)
described in the present interim analysis. However, the outcomes
recorded in the present study are comparable those observed in a larger
prospective study of RFVTA [25].
In summary, 24-month data from the present interim analysis of a
randomized controlled trial suggest equivalence in safety and patient-
reported outcomes of RFVTA and laparoscopicmyomectomy. Treatment
with RFVTA could be considered in the treatment of patients with
symptomatic uterine ﬁbroids who desire uterine conservation.
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